'3+1' mixed-ligand oxorhenium(V) complexes and their inhibition of the cysteine proteases cathepsin B and cathepsin K

被引:21
作者
Baird, Ian R. [1 ]
Mosi, Renee [1 ]
Olsen, Micki [1 ]
Cameron, Beth R. [1 ]
Fricker, Simon P. [1 ]
Skerlj, Renato T. [1 ]
机构
[1] AnorMED Inc, Langley, BC V2Y 1N5, Canada
关键词
cysteine protease inhibitor; cathepsin B; cathepsin K; oxorhenium(V) compounds; '3+1' mixed-ligand complexes;
D O I
10.1016/j.ica.2005.10.058
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
The synthesis of several new oxorhenium(V) complexes containing the '3 + 1' mixed-ligand donor set, ReO(SXS)(SR) (where X = S, O, N(R'); R = alkyl, aryl, heterocylce; R' = H, alkyl, aryl), is described. The X-ray structure for four of these complexes ReO(SN(Ph)S)(SPh) (6), ReO(SN(CH2CH2NMe2)S)(SPhOMe-p) (10), ReO(SOS)(SPh) (29) and ReO(SOS)(SPhNO2-p) (30) was determined. The inhibitory activity of all of the oxorhenium(V) complexes reported herein was evaluated against the cysteine proteases cathepsin B and K in vitro. Compound 25, ReO(SSS)(S-4py) center dot HCl, was the best inhibitor of the series against cathepsin B with an IC50 of 10 nM. Several of the complexes exhibited specificity for cathepsin B over K, suggesting that oxorhenium(V) complexes can be designed to be enzyme specific. The results described in this paper show that the oxorhenium(V) '3 + 1' complexes are potent inhibitors of cathepsin B and K, constituting promising potential for the treatment of cancer and osteoporosis, respectively. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:2736 / 2750
页数:15
相关论文
共 69 条
[1]   SYNTHESIS, STRUCTURE, AND SPECTROSCOPIC PROPERTIES OF COPPER(II) COMPOUNDS CONTAINING NITROGEN SULFUR DONOR LIGANDS - THE CRYSTAL AND MOLECULAR-STRUCTURE OF AQUA[1,7-BIS(N-METHYLBENZIMIDAZOL-2'-YL)-2,6-DITHIAHEPTANE]COPPER(II) PERCHLORATE [J].
ADDISON, AW ;
RAO, TN ;
REEDIJK, J ;
VANRIJN, J ;
VERSCHOOR, GC .
JOURNAL OF THE CHEMICAL SOCIETY-DALTON TRANSACTIONS, 1984, (07) :1349-1356
[2]   SIR97:: a new tool for crystal structure determination and refinement [J].
Altomare, A ;
Burla, MC ;
Camalli, M ;
Cascarano, GL ;
Giacovazzo, C ;
Guagliardi, A ;
Moliterni, AGG ;
Polidori, G ;
Spagna, R .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1999, 32 :115-119
[3]  
ANNASTASSOV V, 2002, 85 CAN CHEM SOC C EX
[4]   N,N-bis(2-mercaptoethyl)methylamine:: A new coligand for Tc-99m labeling of hydrazinonicotinamide peptides [J].
Banerjee, SR ;
Maresca, KP ;
Stephenson, KA ;
Valliant, JF ;
Babich, JW ;
Graham, WA ;
Barzana, M ;
Dong, Q ;
Fischman, AJ ;
Zubieta, J .
BIOCONJUGATE CHEMISTRY, 2005, 16 (04) :885-902
[5]  
Berquin IM, 1996, ADV EXP MED BIOL, V389, P281
[6]  
BEURSKENS PT, 1994, DIRDIF 04 PROGRAM SY
[7]  
Beynon RJ, 1989, PROTEOLYTIC ENZYMES
[8]   Novel therapies for osteoporosis [J].
Biskobing, DM .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (04) :611-621
[9]   Cysteine proteases as therapeutic targets [J].
Brömme, D .
DRUG NEWS & PERSPECTIVES, 1999, 12 (02) :73-82
[10]  
CAMERON BR, UNPUB